ONCR || Breast

20 years after initiating preventive tamoxifen, less breast cancer but no survival benefit

Posted on: 15/12/2014 - 18:55

SAN ANTONIO – Five years of tamoxifen provided 20 years of breast cancer prevention to some at-risk women who took it prophylactically. However, their 20-year all-cause mortality was no different...

Field of Interest: Pulmonology

Type: News Item

SOFT trial endorses selective ovarian suppression in early breast cancer

Posted on: 12/12/2014 - 16:57

SAN ANTONIO – Adding ovarian suppression to 5 years of tamoxifen in women with hormone receptor–positive early breast cancer who remain premenopausal following chemotherapy provides a markedly...

Field of Interest: Oncology

Type: News Item

Adjuvant capecitabine adds no advantage to bisphosphonate in elderly breast cancer patients

Posted on: 12/12/2014 - 14:03

SAN ANTONIO – The combination of capecitabine plus the bisphosphonate ibandronate didn’t improve disease-free survival in elderly women with moderate- or high-risk breast cancers. After 5 years,...

Field of Interest: Oncology

Type: News Item

VIDEO: High TILs associated with less efficacy from trastuzumab

Posted on: 11/12/2014 - 21:01

SAN ANTONIO – Know your patient’s number: Dr. Edith A. Perez of the Mayo Clinic in Jacksonville, Fla., explains in a video interview how the level of stromal tumor infiltrating lymphocytes (TILs) in...

Field of Interest: Oncology

Type: News Item

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Posted on: 11/12/2014 - 14:59

SAN ANTONIO – Roughly one in five women with heavily pretreated, advanced triple-negative breast cancer experienced a durable response to monotherapy using the novel immune checkpoint inhibitor...

Field of Interest: Oncology

Type: News Item

Pembrolizumab shows efficacy in advanced triple-negative breast cancer patients

Posted on: 11/12/2014 - 14:59

SAN ANTONIO – Roughly one in five women with heavily pretreated, advanced triple-negative breast cancer experienced a durable response to monotherapy using the novel immune checkpoint inhibitor...

Field of Interest: Pulmonology

Type: News Item

ROR score aids prognosis after 5 years on tamoxifen

Posted on: 30/10/2014 - 21:26

The risk of recurrence (ROR) score provides clinically meaningful prognostic information after postmenopausal women with early-stage breast cancer complete 5 years of tamoxifen therapy, according to...

Field of Interest: Oncology

Type: News Item

ROR score aids prognosis after 5 years on tamoxifen

Posted on: 30/10/2014 - 21:26

Field of Interest: Pulmonology

Type: News Item

20-year follow-up supports adjuvant radiotherapy for DCIS

Posted on: 13/10/2014 - 21:00

Adjuvant radiotherapy continues to protect against recurrences – albeit “modestly” – for a full 20 years after women undergo breast-conserving surgery for DCIS, according to a report published...

Field of Interest: Pulmonology

Type: News Item

20-year follow-up supports adjuvant radiotherapy for DCIS

Posted on: 13/10/2014 - 21:00

Field of Interest: Oncology

Type: News Item

Newsletters

Stay informed on our latest news!

You are here

Newsletters

Latest Newsletters